News is out! Cohort 7 at 165mg/m2! And look at all those

New Post Public Reply Private Reply Replies (1) Message Board
TheProgressive
News is out! Cohort 7 at 165mg/m2! And look at all those patients on multiple cycles, a great sign!

BEVERLY, MA--(Marketwired - Jan 15, 2014) - Cellceutix Corporation (OTCQB: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, today provides shareholders with an update on the current status of the Company's compounds in development.

Kevetrin, anti-cancer compound in a Phase 1 clinical trial for solid tumors being hosted at Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center:

To date, six cohorts have completed enrollment, with the sixth cohort receiving infusions at 110 mg/m2. Maximum Tolerated Dose ("MTD") has still not been reached. To date, one patient has competed 7 dosing cycles; 2 patients have completed 5 dosing cycles; 1 patient has completed 4 dosing cycles; 1 patient has completed 3 dosing cycles; 8 patients have completed 2 dosing cycles; and 7 patients have completed 1 dosing cycle. A dosing cycle is 28 days.

As disclosed in December (See press release dated December 9, 2013), the Company had filed an amendment with the U.S. Food and Drug Administration ("FDA") to modify the trial protocol to limit the dosing infusion timeframe to a maximum of six hours, versus the current protocol of 30 mg/m2 without a maximum infusion timeframe. As dosing continued to increase without yet reaching a MTD, the infusion duration became a concern as it could become quite lengthy. We are pleased to report that yesterday the FDA accepted our amendment. The FDA approval now allows for enrollment to begin of the seventh cohort under the amended protocol. The safety committee overseeing the trial has approved dosing to be increased to 165 mg/m2 with a 6-hour maximum infusion timeframe for the seventh cohort.

Cellceutix has been advised that requisite documentation is prepared for the planned Phase 1b/2 clinical trial of Kevetrin in combination with Cytarabine for Acute Myelogenous Leukemia to be sponsored by the University of Bologna in Italy, The Italian Cooperative Study Group on Chronic Myeloid Leukemia (ICSG on CML) and Acute Leukemia (GIMEMA Group) and hosted at European clinical sites. We are now in the process of manufacturing a formulation of Kevetrin for this trial.

Prurisol, anti-psoriasis compound being developed under FDA guidance that a 505(b)(2) designation is an appropriate developmental pathway:

Recently, the Company submitted the application to the Institutional Review Board ("IRB") responsible for the planned Phase 1 clinical trial of Prurisol. Upon IRB approval, the Company will immediately file the Investigational New Drug ("IND") application with the FDA to initiate a brief Phase 1 crossover study to confirm that Prurisol converts into abacivir in the human body, as it has been shown to do in animal models. The Phase 1 trial is expected to take approximately 45 days to complete. Following successful completion of the crossover study, Cellceutix will move forward with initiation of a larger Phase 2/3 clinical trial under the pathway of a 505(b)(2), which permits research to immediately move to advanced stages because Prurisol is an ester of an drug already approved by the FDA. Dr. Reddy's Laboratories has already manufactured sufficient quantities of Prurisol for both the Phase 1 and Phase 2/3 trials.

Brilacidin, lead compound in a novel class of synthetic immunomodulatory antimicrobials known as defensin-mimetics:

  • ABSSSI (Acute Bacterial Skin and Skin Structure Infections). On January 10, 2014, Cellceutix received IRB approval for a U.S.-based phase 2b clinical trial in ABSSSI. In this 200-patient study, three brilacidin dosing regimens (two single-dose regimens and one 3-day regimen) will be compared to a standard 7-day regimen of daptomycin. Site initiation visits are planned, after which enrollment will begin.

  • Oral mucositis (OM): As disclosed in December (See press release dated December 20, 2013), the Company filed an application with the U.S. Food and Drug Administration requesting Orphan Drug designation for its oral rinse formulation Brilacidin™-OM as a drug candidate for the prevention of radiation or chemotherapy-induced oral mucositis in patients with head and neck cancer. The company is awaiting a response from the Agency. The company is planning a U.S.-based Phase II trial of Brilacidin-OM for this indication and plans an IRB submission at the end of 1Q 2014.

  • Ophthalmic infections: As disclosed in November (See press release dated November 4, 2013) 2013), the company has identified ocular infections, such as keratitis, as an area of unmet medical need and significant commercial potential, based on positive preclinical data supporting safety, antimicrobial efficacy, and prolonged residence time on the ocular surface with minimal systemic exposure. The Company has received proposals for the necessary formulation and will shortly select a manufacturer.

  • Otitis media/externa: Preclinical studies in animals have begun and formulation development is in progress.

"We are extremely pleased with the advancements of Kevetrin, Brilacidin and Prurisol; their developments as a testament to the dedication and hard work of our team," comments Leo Ehrlich, Chief Executive Officer of Cellceutix. "Looking back at 2013, our Company has experienced tremendous growth, moving forward in clinical trials, adding very promising compounds to our portfolio with the acquisition of PolyMedix assets, doubling the size of our laboratory and strengthening our financial position. As satisfied as we are with the accomplishments of 2013, we have higher expectations for 2014 and again are striving to be an even better, more formidable company at this time next year."

 

Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Zesty Takes Kubernetes Cost Control Into GPU Territory

Updated Category News Views 88

GPU waste has become the sort of cloud bill nobody wants to explain upstairs. A company buys scarce, expensive accelerators for AI work, then discovers that real workloads do not politely consume resources in neat, permanent blocks. Demand jumps, memory needs shift, and somebody either over-allocates to avoid trouble or under-allocates and gets ugly out-of-memory...

Continue Reading
Chargeback AI Still Has a Costly Last-Mile Problem

Updated Category News Views 41

A corrected headline is a small wrinkle, but the underlying chargeback mess is not. Chargeflow and Juniper Research surveyed 121 senior executives at U.S. and U.K. businesses with at least $100 million in annual gross merchandise value, and the useful takeaway is painfully clear: merchants are putting AI on the label without rebuilding the machinery underneath. That...

Continue Reading
RLX Revenue Soars, but European Margins Need Proof

Updated Category News Views 38

Revenue can wear a fancy suit while earnings arrive in work boots, and RLX Technology's third quarter is exactly that kind of report. The newly consolidated European distribution business pushed third-quarter revenue to RMB1.92 billion, up 69.7% year over year. That is a real jump, not pocket change. But the same acquisition also changed the mix, squeezed the blended...

Continue Reading
Klarna’s Cash Burn Puts Disclosure Questions in Focus

Updated Category News Views 98

A $383 million operating cash drain can turn a growth story sour in a hurry. Klarna Group plc delivered exactly that kind of unpleasant jolt in its third-quarter 2026 report: a net loss of $65 million, or roughly $0.19 per share, alongside negative operating cash flow of $383 million over the first nine months of 2026. The per-share loss landed worse than the $0.13 to...

Continue Reading
COP31 Tests Whether Climate Warnings Move Power Systems

Updated Category News Views 82

A weather alert that never reaches the control room is just expensive wallpaper. That was the useful, unsentimental thread running through a COP31 side event in Ankara on November 13: climate diplomacy is not worth much if grid operators, project owners and financiers do not change what they do when the forecast turns ugly. Implementation Means Changing Operations COP31...

Continue Reading
Vanguard's Digital Win Matters More Than a Trophy

Updated Category News Views 182

A wealth manager’s website rarely earns applause, but a bad one can sure as hell lose trust fast. Vanguard’s move to No. 1 from No. 3 in the 2025 ranking for advised-investor website satisfaction is worth noticing because it hits the unglamorous part of wealth management that clients actually live with: checking accounts, understanding a plan, moving cash, and...

Continue Reading
Retainers Are the Unflashy Finish to Orthodontic Care

Updated Category News Views 98

A straight smile has an inconvenient habit of remembering where it came from. That is the plainspoken point in Dr. Michael McClain’s discussion of retainers after braces or Invisalign: the dramatic part of orthodontic treatment may be over when appliances come off, but the maintenance phase has barely started. It is not glamorous, and plenty of people probably wish it...

Continue Reading
TSA at 25: Security Mission Meets a Tough Travel Reality

Updated Category News Views 111

Twenty-five years after its birth from catastrophe, TSA is still carrying a job nobody should take lightly. The agency marked its anniversary on November 19, 2026, looking back to the September 11, 2001 attacks that led to federalized aviation screening and a permanent reshaping of how Americans move through airports. This is not the sort of milestone that deserves...

Continue Reading
Mindstream’s Jordan AI Campus Faces Its First Real Test

Updated Category News Views 65

Jordan’s AI ambitions just got attached to a very large gas meter. Mindstream Energy has unveiled a plan for an AI-ready data-center campus at Al-Risha in Mafraq Governorate, built around dedicated natural-gas generation rather than a conventional dependence on the utility grid. The headline number is 400 megawatts of eventual capacity. The number that matters first is...

Continue Reading
Automotive Laminates: Small Market, Real EV Leverage

Updated Category News Views 223

Cabin trim has become a surprisingly serious battleground, and that is the whole point of this automotive laminates story. Nobody buys a vehicle because somebody bragged about a multilayer film behind the door panel. Yet the materials under the fingertips, beneath the carpet, and around the dashboard increasingly decide whether an interior feels cheap, quiet, durable, or...

Continue Reading

Top 5 Most Recently Viewed Articles

Spectral Capital Reaches Key Patent Goals in Quantum Technology

Updated Category News Views 129

Major Developments at Spectral Capital Spectral Capital Corporation (OTCQB: FCCN), a visionary company in quantum technology, is excited to announce a significant achievement in its ongoing pursuit to lead the quantum computing domain through a robust patent strategy. Achieving Patent Milestones Recently, the company shared that it has successfully filed 104 provisional...

Continue Reading
Nexalin Technology Successfully Raises $5 Million in Offering

Updated Category News Views 219

Nexalin Technology Successfully Completes $5 Million Offering Nexalin Technology, Inc. (NASDAQ: NXL; NXLIW) has recently announced the successful closing of its underwritten public offering, which involved the sale of 3,850,000 shares of common stock at a price of $1.30 per share. This offering garnered close to $5 million in gross proceeds for the company, reflecting a...

Continue Reading
Louis Hernandez Jr. Launches 'Digital Tsunami' Enhancing Tech

Updated Category News Views 522

A New Chapter in Technology with 'Digital Tsunami' In a thrilling development for the tech industry, Louis Hernandez Jr. has unveiled his latest book, 'Digital Tsunami.' This publication serves as a clarion call for change, urging both industry leaders and consumers to prepare for a wave of innovative advancements. As technology rapidly evolves, Hernandez emphasizes the...

Continue Reading
Insights from Booking Holdings at the Citi Global TMT Conference

Updated Category News Views 141

Exciting Presentation by Booking Holdings at Citi Conference Booking Holdings (NASDAQ: BKNG) is set to take the stage at the Citi 2025 Global TMT Conference, an exciting event for technology, media, and telecom industries. The event will feature the insightful Chief Financial Officer, Ewout Steenbergen, who will engage in an enriching fireside chat. Details of the...

Continue Reading
Bluevine Reports Small Business Optimism and Growth Ahead

Updated Category News Views 291

Small Business Confidence on the Rise Bluevine's recent survey sheds light on the optimism radiating from small business owners (SBOs) despite ongoing economic challenges. Their 2024 End-of-Year Business Owner Success Survey, commonly referred to as the BOSS Report, reveals a significant trend: SBOs are developing strategies to thrive even amidst uncertainty. Insights...

Continue Reading